by Sam Eskandari | Aug 2, 2017 | News
August 2, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces that it has agreed to amend the terms of share purchase warrants (“Warrants”) originally issued in February 2017. Each...
by Sam Eskandari | Jul 24, 2017 | News
July 24th, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of Mr. Peter Doig to the advisory board of Veritas Pharma. Mr. Doig is a...
by Sam Eskandari | Jul 12, 2017 | News
July 11, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of RwE Growth Partners, Inc. to evaluate the Company’s $1.50 million investment...
by Sam Eskandari | Jul 10, 2017 | News
July 10th, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that it is preparing to begin construction of a state-of-the-art cannabis growing facility upon receiving Health Canada’s license under Access to...
by Sam Eskandari | Jun 6, 2017 | News
June 6, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), as an ACMPR applicant would like to notify its investors that Health Canada is introducing several improvements that aim to streamline the ACMPR licensing process....
